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Letter to the editors
The use of ustekinumab in refractory treatment of psoriatic 
arthritis
Uso de ustequinumabe no tratamento refratário da artrite psoriásica
To the editors:
We had the opportunity of read the review article of 
Goldenstein-Schainberg et al.1 about the most important 
aspects of psoriatic arthritis (PA) over the years. Related 
to the therapeutic aspects, it is concluded that biologic 
agents, especially TNF inhibitors (infliximab, etarnecept, 
adalimumab and golimumab), are used as drugs of last 
line in refractory cases of the disease. Then, based on ex-
isting literature, we show our agreement in this last state-
ment.2,3
However, we consider important to mention alternative 
therapies. In the clinical trial of Griffiths et al., the au-
tors studied 900 patients with PA who didn’t respond to 
treatment with one biologic agent. In order to get a bet-
ter clinical response, they compared two biologic agents: 
ustekinumab – last biologic agent (monoclonal antibody) 
approved in 2009 – and etanercept. As a result, they found 
that patients with ustekinumab had a better and faster 
clinical response, with both dermatological and joint 
improvement.4 Cuchacovich reported the same compari-
son in 2011 and reassured the findings of Griffiths with 
ustekinumab.2 Furthermore, in the case report of Cuchaco-
vich, the clinical improvement was demonstrated with the 
use of the combination of the two biologic agents men-
tioned earlier: ustekinumab and etanercept.3 Above all, 
to demonstrate the safety of ustekinumab, Cuchacovich 
reported its use in patients who were refractory to photo-
therapy, systemic corticosteroids and biologic therapy (in-
cluding TNF inhibitors). The result not only was favorable 
but also improved the clinical response in the psoriasis 
area and in the severity index.2
Furthermore, another biologic agent recommended 
in this review, efalizumab, was withdrawn from the U.S 
market in June 2009 by the FDA because of potential risk 
to patients of developing progressive multifocal leukoen-
cephalopathy (PML).5 This information is necessary to em-
phasize that this drug should not be recommended as a 
treatment for skin manifestations in PA patients as it was 
suggested in the study of Goldenstein-Schainberg et al.1 
In fact, PML is known as a serious life-threatening condi-
tion and a devastating neurological disease. It is usually 
caused by the JC virus but years ago it was emerged as a 
result of treatment with biologic agents in several rheu-
matic diseases.6
In conclusion, ustekinumab should be included in ther-
apeutic protocols for PA treatment refractory to biological 
drugs. It is also important not to encourage the use of efal-
izumab for any kind of rheumatic disease. We need more 
studies to demonstrate the safety of new biological drugs 
different from ustekinumab.
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